Navigation Links
Boehringer Ingelheim Broadens Its Breast Cancer Clinical Trial Program for the Investigational Compound Afatinib
Date:9/6/2011

a href="http://clinicaltrials.gov/ct2/show/NCT01125566?term=LUX-Breast+1&rank=1">http://clinicaltrials.gov/ct2/show/NCT01125566?term=LUX-Breast+1&rank=1.

Afatinib in HER2-Treatment Failures (1200.98)

This global, non-randomized, open-label study began in May 2011 and will investigate the efficacy and safety of afatinib alone and in combination with weekly paclitaxel or weekly vinorelbine (in patients who progress on afatinib monotherapy within this trial) as treatment in patients with HER2-overexpressing, metastatic breast cancer, who failed HER2-targeted treatment in the neoadjuvant or adjuvant setting. The study will recruit approximately 120 patients.  The primary endpoint of the study is objective response rate; secondary endpoints include best overall response (OR) during each treatment period, duration of OR, PFS and safety.  For more information, please visit http://clinicaltrials.gov/ct2/show/NCT01271725?term=afatinib+1200.98&rank=1.  

Afatinib in erbB2 (HER2)-Overexpressing Inflammatory Breast Cancer (1200.89)

This non-randomized, open-label study will investigate the efficacy and safety of afatinib alone and in combination with weekly vinorelbine (in patients who progress on afatinib monotherapy within this trial) as treatment in patients with HER2-overexpressing, locally advanced or metastatic inflammatory breast cancer. The study will include approximately 40 patients (combined in the United States and globally) who have or have not failed prior trastuzumab treatment. The primary endpoint of the study is clinical benefit rate assessed by complete response, partial response and stable disease for at least six months; secondary endpoints include OR, duration of OR, PFS and safety.  For more information, please visit

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
2. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
3. Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
4. Boehringer Ingelheim Unveils Diabetes Pipeline
5. Boehringer Ingelheim Animal Health Closes Deal to Acquire a Significant Portion of the Fort Dodge Animal Health Business From Pfizer
6. Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile
7. New Boehringer Ingelheim Science Quest Mobile Laboratory Brings Hands-On Science Education to Priority Connecticut Elementary Schools
8. Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010
9. -- Neurocrine Announces a Second Corporate Collaboration Within Twenty-Four Hours -- Neurocrine Biosciences Announces a Worldwide Collaboration With Boehringer Ingelheim to Research and Develop GPR119 Agonists for Type II Diabetes
10. Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes
11. Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DARTâ„¢-Based Antibody Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... AARP Foundation today announced it has established a ... severe cold weather that has gripped much of the nation. ... need; so to support these emergency relief efforts AARP and ... could mean up to $500,000 in aid. The matching program ...
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ) announces that ... to the announced tender offer for all of the outstanding shares ... of the waiver, the transaction is no longer conditional on OFT ... 24, 2014 following the currently scheduled expiration time, subject to the ...
(Date:1/15/2014)... 2014  In an unprecedented effort to curb the spread of "superbugs" ... transport vehicles, an advanced and portable UV germicidal lamp manufactured by ... time. In order to prevent EMS paramedics and ... West Palm Beach Fire Rescue is the first ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Superbugs No Longer Ride In Rescue Vehicles 2
... Oct. 27 Pharmos Corporation (Pink Sheets: PARS ... nine-month period ended September 30, 2010. These results are included ... been filed with the SEC. During the quarter ... potential partners for Dextofisopam, its drug for irritable bowel syndrome ...
... N.J., Oct. 27 Systech International, innovator of ... Pac Automation, a leading supplier of end-of-line packaging ... integrated solution for global serialization requirements at Pack ... attendees have the opportunity to examine first hand ...
Cached Medicine Technology:Pharmos Corporation Reports 2010 Third Quarter Results 2Pharmos Corporation Reports 2010 Third Quarter Results 3Pharmos Corporation Reports 2010 Third Quarter Results 4Systech and Pester Pac Automation Exhibit Integrated Serialization Solution at Pack Expo 2010 2
(Date:4/17/2014)... MANHASSET, NY In a review published in the ... MD, president of The Feinstein Institute for Medical Research, ... the medical community,s approach to treating sepsis, ... 200,000 Americans. , Sepsis occurs when molecules released into ... inflammation throughout the body. Inflammation is necessary for maintaining ...
(Date:4/17/2014)... has created a new technology for modifying human ... the body and selectively target cancer and other ... that monitor and modify human physiology is a ... existing technology enabled bioengineers to build such devices ... in a customized fashion. , "The project addressed ...
(Date:4/17/2014)... (April 17, 2014) Doctors who treat patients ... lymphangioleiomyomatosis (LAM) can face an agonizing treatment decision. ... the disease and help relieve shortness of breath. ... and sirolimus can cause potentially fatal complications following ... Dr. Daniel Dilling, medical director of Loyola University ...
(Date:4/17/2014)... The cause of neuronal death in Parkinson,s disease ... neurons may be mistaken for foreign invaders and killed ... way autoimmune diseases like type I diabetes, celiac disease, ... was published April 16, 2014, in Nature Communications ... idea in Parkinson,s disease; but if true, it could ...
(Date:4/17/2014)... a new mechanism that allows blood to enter the ... and the Salk Institute have opened the door to ... damage. , A complex and devastating neurological condition, stroke ... for disability in the U.S. The blood-brain barrier is ... into the brain, causing the permanent deficits in movement ...
Breaking Medicine News(10 mins):Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Building 'smart' cell-based therapies 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:Is Parkinson's an autoimmune disease? 2Health News:Study IDs new cause of brain bleeding immediately after stroke 2
... Minority Quality Forum Launches First U.S. HIV/AIDS Atlas , ... today launched a groundbreaking HIV/AIDS Atlas ( http://www.MapHIV.org ... epidemic in communities across the United States. The Atlas ... location for the first time, painting a comprehensive picture of ...
... Perfect Time for Fitness! , , LOS ANGELES, June 22 ... in the park or along the beach. Now a brand new ... fitness equipment on wheels, but with a unique design to allow ... a new concept of fitness, will be introduced to California starting ...
... , DentaBurst(TM) delivers an on-the-go oral care solution to ... NEW YORK, June 22 Crown Consumer Brands today ... the original proven technology will remain intact, an improved, ... will accompany this highly anticipated re-launch. , ...
... MUSCLEPHARM(R) LLC, the rising star of the Sports Nutrition ... through each of Vitamin Shoppe,s 400+ locations nationwide. , ... launch of our entire line of products," MUSCLEPHARM president ... athletes in nearly every neighborhood across the nation! Vitamin ...
... Transcend Medical, Inc., an ophthalmic device company dedicated ... announced today that it has closed a $35 million ... of its Transcend CyPass(TM) System, a novel proprietary system ... Lead investor HLM Venture Partners, along with other new ...
... Magnetic Resonance Center of the University Children,s Hospital ... in MR-guided, non-invasive neurosurgery. Ten patients have been ... ultrasound. This fully non-invasive procedure opens new horizons ... brain disorders. In the context of a ...
Cached Medicine News:Health News:MapHIV.org Shows 18% of Georgia's Counties are Seriously Impacted by HIV 2Health News:MapHIV.org Shows 18% of Georgia's Counties are Seriously Impacted by HIV 3Health News:Pumgo Fitness Scooter Will Highlight Venice Beach This Summer 2Health News:Crown Consumer Brands Re-Launches DentaBurst(TM) Freshening Teeth Cleaners 2Health News:MUSCLEPHARM Products Hit Vitamin Shoppe Shelves With a Bang! 2Health News:Transcend Medical Raises $35 Million Series B Round Towards Development of Novel Glaucoma Treatment 2Health News:Successful neurosurgery with transcranial MR-guided high-intensity focused ultrasound 2Health News:Successful neurosurgery with transcranial MR-guided high-intensity focused ultrasound 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: